Advanced search
Publication Cover
Current Medical Research and Opinion Volume 36, 2020 - Issue 2
Submit an article Journal homepage
261
Views
0
CrossRef citations to date
0
Altmetric
Diabetes

Lixisenatide versus insulin glulisine on top of insulin glargine in patients with type 2 diabetes mellitus: a cost-per-responder analysis in China

Peng MenDepartment of Pharmacy, Peking University Third Hospital, Beijing, China; ;Institute for Drug Evaluation, Peking University Health Science Center, Beijing, China;
,
Chaoyun LiHealth Economics and Outcome Research, Sanofi, Shanghai, China;
,
Suodi ZhaiDepartment of Pharmacy, Peking University Third Hospital, Beijing, China; ;Institute for Drug Evaluation, Peking University Health Science Center, Beijing, China; Correspondence[email protected]
&
Shuli QuReal World Insights, IQVIA, Shanghai, China
Pages 213-217 | Received 17 May 2019, Accepted 29 Aug 2019, Published online: 11 Sep 2019

References

  • Cho NH, Shaw JE, Karuranga S, et al. IDF diabetes atlas: global estimates of diabetes prevalence for 2017 and projections for 2045. Diabetes Res Clin Pract. 2018;138:271–281.
  • Xu Y, Wang L, He J, et al. Prevalence and control of diabetes in Chinese adults. JAMA. 2013;310(9):948–959.
  • Yang W, Lu J, Weng J, et al. Prevalence of diabetes among men and women in China. N Engl J Med. 2010;362(12):1090–1101.
  • American Diabetes A. 8. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes-2018. Diabetes Care. 2018;41(Suppl 1):S73–S85.
  • Society CD. Guidelines for the prevention and treatment of type 2 diabetes in China (2017 Edition). Chin J Diabetes Mellitus. 2018;1:4–67.
  • Society CD. Guidelines for the prevention and treatment of type 2 diabetes in China (2013 Edition). Chin J Endocrinol Metab. 2014;10:839–942.
  • American Diabetes A. Standards of medical care in diabetes–2009. Diabetes Care. 2009;32(Suppl 1):S13–S61.
  • Ahren B. Glucagon-like peptide-1 receptor agonists for type 2 diabetes: a rational drug development. J Diabetes Investig. 2018;10:196–201.
  • McCarty D, Coleman M, Boland CL. Lixisenatide: a new daily GLP-1 agonist for type 2 diabetes management. Ann Pharmacother. 2017;51(5):401–409.
  • Rosenstock J, Guerci B, Hanefeld M, et al. Prandial options to advance basal insulin glargine therapy: testing lixisenatide plus basal insulin versus insulin glulisine either as basal-plus or basal-bolus in type 2 diabetes: the GetGoal duo-2 trial. Diabetes Care. 2016;39(8):1318–1328.
  • Afonso M, Ryan F, Pitcher A, et al. Evaluating drug cost per responder and number needed to treat associated with lixisenatide on top of glargine when compared to rapid-acting insulin intensification regimens on top of glargine, in patients with type 2 diabetes in the UK, Italy, and Spain. J Med Econ. 2017;20(6):633–639.
  • National Bureau of Statistics of China. Statistical Communiqué of the People's Republic of China on the 2018 National Economic and Social Development. http://www.stats.gov.cn/english/PressRelease/201902/t20190228_1651335.html
  • Moreira RO, Cobas R, Lopes Assis Coelho RC. Combination of basal insulin and GLP-1 receptor agonist: is this the end of basal insulin alone in the treatment of type 2 diabetes? Diabetol Metab Syndr. 2018;10(1):26.
  • Seino Y, Min KW, Niemoeller E, et al. Randomized, double-blind, placebo-controlled trial of the once-daily GLP-1 receptor agonist lixisenatide in Asian patients with type 2 diabetes insufficiently controlled on basal insulin with or without a sulfonylurea (GetGoal-L-Asia). Diabetes Obes Metab. 2012;14(10):910–917.
  • Riddle MC, Aronson R, Home P, et al. Adding once-daily lixisenatide for type 2 diabetes inadequately controlled by established basal insulin: a 24-week, randomized, placebo-controlled comparison (GetGoal-L). Diabetes Care. 2013;36(9):2489–2496.
  • Charbonnel B, Bertolini M, Tinahones FJ, et al. Lixisenatide plus basal insulin in patients with type 2 diabetes mellitus: a meta-analysis. J Diabetes Complicat. 2014;28(6):880–886.
  • Raccah D, Lin J, Wang E, et al. Once-daily prandial lixisenatide versus once-daily rapid-acting insulin in patients with type 2 diabetes mellitus insufficiently controlled with basal insulin: analysis of data from five randomized, controlled trials. J Diabetes Complicat. 2014;28(1):40–44.
  • Yang W, Min K, Zhou Z, et al. Efficacy and safety of lixisenatide in a predominantly Asian population with type 2 diabetes insufficiently controlled with basal insulin: The GetGoal-L-C randomized trial. Diabetes Obes Metab. 2018;20(2):335–343.
  • Huetson P, Palmer JL, Levorsen A, et al. Cost-effectiveness of once daily GLP-1 receptor agonist lixisenatide compared to bolus insulin both in combination with basal insulin for the treatment of patients with type 2 diabetes in Norway. J Med Econ. 2015;18(8):573–585.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.